The Amebiasis Treatment Can Offer Opportunities for Payers as Consumer Demand for Cost-Effective Pharmaceuticals Rises

Amebiasis is an infection of the intestine caused by a parasite Entamoeba Histolytica.

Amebiasis is an infection of the intestine caused by a parasite Entamoeba Histolytica. Symptoms of this disease include loose stool, abdominal cramping, and stomach pain. Amebiasis is common in regions with low developed sanitation facilities such as Asia Pacific, Central America, South America, and some parts of Africa. Amebiasis is mainly transmitted through water or food contaminated with Entamoeba Histolytica. Amebiasis can lead to diarrhea (with or without blood) in both adults and children, leading to high morbidity and mortality. The organism, Entamoeba Histolytica, can damage organ and may require surgical intervention, if the colon and other tissues have undergone perforation. However, amebiasis can be treated with some antibiotic, anti- parasitic, and antiprotozoal drugs such as metronidazole, paromomycin, and tinidazole. Diagnosis of this disease is usually made by microscopic identification of the microorganism in a stool specimen.

Get Exclusive Sample Report at:

Amebiasis Treatment Market Drivers

Increasing approvals and launches of new drugs indicated for the treatment of amebiasis is expected to be a major factor for growth of amebiasis treatment market. For instance, in 2017, Dr. Reddy's Laboratories received U.S. Food and Drug Administration (FDA) approval for its Minolira (minocycline) extended-release tablets, indicated for the treatment of a variety of bacterial infections and as adjunctive therapy in acute intestinal amebiasis. Moreover, in 2016, Rising Pharmaceuticals, Inc.—a subsidiary of Aceto Corporation—launched Metronidazole Tablets, 250mg and 500mg, generic version of Flagyl manufactured by G.D. Searle, LLC’s, indicated for the treatment of amebiasis and a variety of anaerobic bacterial infections. In 2016, Mylan Pharmaceuticals Inc. received ANDA approval for its Doryx (Doxycycline Hyclate) Delayed-Release Tablets, 50 mg, indicated for the treatment of acute intestinal amebiasis. Furthermore, increasing prevalence of amebiasis in region with poor sanitation facilities such as Africa and some countries in Asia Pacific is expected to lead to increasing demand for its treatment, which in turn is expected to drive growth of the amebiasis treatment market in the near future. For instance, according to data published by International Research Journal of Biological Sciences, in 2013, the prevalence of amebiasis among school children in Lafia, Nigeria was around 26.7%. The highest prevalence of amebiasis was 40.0% in children of Government Secondary School Tudun Kauri, Lafia. This high prevalence of amebiasis was due to poor environmental/drainage system, unhygienic methods of disposing sewage, and shortage of clean water supply.

Amebiasis Treatment Market Regional Analysis

Africa is expected to show a significant growth in the global amebiasis treatment market over the forecast period, owing to high prevalence rate of amebiasis due to poor sanitation and low availability of clean drinking water. For instance, according to data published by United Nations Department of Economic and Social Affairs (UNDESA), in 2014, around 115 people in Africa die every hour from diseases linked to poor sanitation, poor hygiene, and contaminated water. In Sub-Saharan Africa around 40% of the 783 million people do not have access to a clean source of drinking water. Furthermore, Asia Pacific region is expected to show significant growth in amebiasis treatment market over the forecast period, owing to increasing prevalence of amebiasis in some rural areas of India and China. For instance, according to data published on National Health Portal of India, in 2015, amebiasis affected about 15% of the total population in India.

Amebiasis Treatment Market Restraint

Amebiasis is an infectious disease, which is native to areas with poor sanitation facilities and lack of clean drinking water supply. The people living in rural areas have low access to drugs, due to low presence of hospitals and healthcare professionals. The absence of good healthcare facilities and low access to drugs is expected to be major factor restraining growth of the amebiasis treatment market.

Amebiasis Treatment Market Key Players

Key players operating in amebiasis treatment market include Pfizer Inc., Impax Laboratories, Lupin Pharmaceuticals, Inc., Sanofi, Actelion Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Inc., Heritage Pharmaceuticals Inc., Mission Pharmacal Co., Novel Laboratories, and others. Key players in the market are focusing on launching generic versions of branded medicines indicated for treatment of amebiasis. For instance, in 2017, Mayne Pharma Group Limited received FDA approval for its Doxycyline Hyclate IR Tablets, first generic to Acticlate. Doxycycline Hyclate 75 mg and 150 mg are tetracycline class drugs indicated for adjunctive therapy for acute intestinal amebiasis.

Inquire Here Before Purchase of Research Report @

Amebiasis Treatment Market Taxonomy:

The global amebiasis treatment market is segmented on the basis of drug type, distribution channel, and region:

By Drug Type-

Chloroquine phosphate

By Distribution Channel-

Online Pharmacies
Retail Pharmacies

By Region

North America
Latin America
Asia Pacific
Middle East

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702


There are no comments yet. You need to be logged in to comment.

The Indymedia Network

Latin America
United States
East Asia
South Asia
West Asia